NCT02091245 - Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2018

Study Completion Date

December 31, 2025

Conditions

Relapsed Acute Lymphoblastic Leukemia (ALL)Refractory Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)Refractory Acute Myelogenous Leukemia (AML)Relapsed Mixed Lineage LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Biphenotypic LeukemiaRefractory Biphenotypic LeukemiaChronic Myelogenous Leukemia (CML) in Blast Crisis

Interventions

DRUG

KPT-330

Trial Locations (10)

10032

Columbia University Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

30322

Children's Healthcare of Atlanta, Atlanta

53226

Children's Hospital of Wisconsin, Milwaukee

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

94143

UCSF, San Francisco

98101

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston